EAEU Hits Hurdles In Implementing New Pharma, Medical Product Regulations
This article was originally published in SRA
Executive Summary
Pharmaceutical and medical product companies operating in countries of the Eurasian Economic Union (EAEU) will soon be facing a new set of regulations that among other things are intended to establish a single EAEU market with free movement of medicines and medical goods, introduce a new decentralized drug approvals procedure, and help bring down pharmaceutical prices through greater competition.
You may also be interested in...
Eurasian Common Medicines Market Gets Off The Ground
The new regulatory framework in the Eurasian Economic Union is now in place and the first drug approval applications have been filed under the mutual recognition system. Applications are expected to rise significantly in 2019 once IT systems are fully in place and more experience has been gained.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.